Navin Fluorine International Limited

NAVINFLUOR

Sector: ChemicalsSub-sector: Specialty Chemicals
Qtr Score Rank 4 / 57 (Top 95 percentile)Growth Score Rank 3 / 51 (Top 96 percentile)

Quarterly Score

Trend: Improving
Strong improvement - Recent 3Q avg 9.23 vs 2Q avg 8.85 (+0.38)

Showing the latest 12 quarterly points (newest to oldest).

Score context (latest 12 quarters)

Q3 FY2025
8.5

Management maintained guidance to exit FY25 at ~25% EBITDA margins. Reaffirmed $100 million CDMO revenue target for FY27. New R32 capacity (4,500 MT) to commission in Feb 2025; AHF project (₹450 Cr) on track for early FY26.

Quarter summary

  • The company reached a record quarterly revenue run rate exceeding ₹600 crore, signaling a scale-up across all three business verticals (HPP, Specialty, CDMO).
  • HPP vertical benefited from a favorable mix and volume growth in HFO, R22, and R32, while the Specialty segment saw traction from new molecule launches and improved plant loading.

Rationale

  • Significant margin recovery with operating EBITDA margins expanding to 24.3% in Q3 FY25 from 15.13% YoY and 20.7% QoQ, driven by improved HPP realizations and higher capacity utilization.
  • Major execution milestone achieved with the commissioning of the ₹540 crore agro specialty plant at Dahej; commercial dispatches have commenced with a target peak revenue of ~₹515 crore within two years.
Q4 FY2025
9.2

Management maintained strong visibility with the AHF project completion expected in Q2 FY26 and cGMP4 Phase I (INR 160 crores capex) on track for Q3 FY26. Reiterated an aspirational CDMO revenue milestone of US$100 million within a 2-year horizon.

Quarter summary

  • Successfully commercialized the second R32 plant in March 2025, reaching optimal capacity utilization immediately due to robust global and domestic demand.
  • Pivot toward high-purity 'Advanced Materials' confirmed through a technology tie-up with BUSS ChemTech for N5-grade electronic and solar-grade Hydrofluoric acid (HF).

Rationale

  • Achieved record annual revenue of INR 2,349 crores (+14% YoY) and record quarterly revenue of INR 701 crores (+16% YoY), demonstrating strong execution across HPP, CDMO, and Specialty Chemicals.
  • Significant margin expansion with Q4 FY25 EBITDA margins reaching 25.5% (up 720 bps YoY from 18.3%) and FY25 margins at 22.7% (up 340 bps YoY from 19.3%).
Q1 FY2026
9.0

Management indicated EBITDA margins will remain 'north of 25%' for FY26. Annual capex frame raised to INR 700–1,000 cr. Strong visibility for Specialty and CDMO through FY26/FY27 based on firm POs and long-term contracts.

Quarter summary

  • Successful commercialization and ramp-up of the R32 project to optimal capacity, capitalizing on firm global refrigerant gas pricing.
  • Strategic pivot toward Advanced Materials and Electronic-grade HF through partnerships with Chemours (Opteon) and Buss ChemTech AG.

Rationale

  • Exceptional financial outperformance with revenue growing 39% YoY (INR 725 cr) and PAT surging 129% YoY (INR 117 cr), driven by strong execution across all three business verticals.
  • Significant margin expansion of 935 bps YoY to 28.5%, fueled by operating leverage (2/3 of gain) and robust pricing in the HPP segment/R32 (1/3 of gain).
Q2 FY2026
9.2

Management raised FY26 EBITDA margin guidance to 28-30% (from 25%). Strong order book visibility through CY2026 for Specialty. New R32 capacity (15k MTPA) expected by Q3 FY27 with peak revenue of INR 600-825 Cr; MPP debottlenecking expected by Q3 FY27 with INR 140-160 Cr revenue potential.

Quarter summary

  • Broad-based execution success with all three business divisions reporting strong double-digit growth and operating at optimal capacities.
  • Strategic focus on high-value refrigerant gases (R32) to capture global supply tightening resulting from Kigali Amendment production cuts in the West and China.

Rationale

  • Exceptional financial trajectory with H1 FY26 revenue up 42% YoY to INR 1,484 crores and EBITDA/PAT more than doubling compared to H1 FY25.
  • Significant margin expansion and guidance upgrade: Q2 EBITDA margins reached 32.5% (up from 20.7% YoY), prompting management to raise full-year FY26 margin guidance to the 28-30% range (previously 25%).
Q3 FY2026Latest
9.5

Strong visibility maintained; CDMO cGMP-4 engagement provides 3-year revenue visibility. Wave-2 CAPEX timelines: Chemours (Q1 FY27), R32 15,000 MTPA expansion (Q3 FY27), and MPP debottlenecking (Q3 FY27).

Quarter summary

  • Transition from 'Wave-1' to 'Wave-2' CAPEX phase, with the critical AHF mother plant and cGMP-4 facility now operational and revenue-generating.
  • Strategic pivot toward the high-value semiconductor and electronics value chain, aligned with India's Semiconductor Mission 2.0 and global trade tailwinds.

Rationale

  • Exceptional top-line and bottom-line growth with Q3 revenue up 47% YoY (₹892 cr) and Operating EBITDA up 109% YoY (₹308 cr), demonstrating massive operating leverage.
  • Significant margin expansion of 1,020 bps YoY to 34.5% in Q3, with management raising the sustainable annual EBITDA margin floor to ~30% (+/- 200 bps) from the historical 25%.

Future Growth Prospects

Growth score: 9.2Visibility: 85%Updated: 26 Feb 2026, 01:12 am

Catalysts (next 12-24 months)

Total triggers: 4Visible per view: 1 / 2 / 3Slides: 4

Swipe or use arrows to browse all triggers.

capacityQ3 FY27Impact: revenueQty: 825 ₹ Cr

HFC (R32) Capacity Expansion (15,000 MTPA)

Timeline

  • announcedQ2 FY26 · concall

    Board approved a capex of INR236.5 crores for setting up additional HFC capacity.

    New project approval

  • in progressQ3 FY26 · concall

    CAPEX for incremental HFC capacity equivalent up to 15,000 MTPA of R32 is progressing as planned.

    On track for Q3 FY27 commissioning

Supporting evidence

• Q2FY26 · concall · This asset is expected to generate a peak annual revenue of INR600 crores to INR825 crores on completion.

productQ1 FY27Impact: revenueQty: 3 null

Chemours Project (Opteon Liquid Cooling Fluid)

Timeline

  • in progressQ2 FY26 · concall

    Chemours project... progressing well and is on track for completion by Q1 of FY '27.

    Timeline firmed up

  • in progressQ3 FY26 · ppt

    Chemours project is on track for completion in Q1FY27

    On track

Supporting evidence

• Q3FY26 · concall · The liquid cooling market, I believe, is close to about $3 billion potential. Two-phase cooling is one part to support data center growth.

capacityQ3 FY27Impact: revenueQty: 160 ₹ Cr

MPP Capacity Debottlenecking at Dahej

Timeline

  • announcedQ2 FY26 · concall

    Board has approved capex of INR75 crore for debottlenecking of MPP capacity at Dahej.

    New approval for Specialty vertical

Supporting evidence

• Q2FY26 · concall · This capex will contribute to INR140 crores to INR160 crores per annum on completion.

capacityQ3 FY26Impact: revenueQty: 3 null

cGMP-4 Phase-1 Facility Commercialization

Timeline

  • commissionedQ3 FY26 · concall

    Started commercial supplies... engagement provides strong revenue visibility over the next three years.

    Moved from validation to commercialization

Supporting evidence

• Q3FY26 · concall · cGMP-4 Phase-1 facility has been commissioned... Post successful validation of batches, we started commercial supplies during the quarter.

Variant perception

Non-consensus view
Consensus

Consensus likely underappreciates the exponential operating leverage; EBITDA growth is doubling revenue growth rate (114% vs 44% in 9M).

Upside
  • Entry into semiconductor value chain (BF-3, electronic grade HF) is in evaluation stages with global niche players.
Show more (1)
  • Wave-1 CAPEX completion shifts company from 'capex mode' to 'harvest mode' earlier than peer cycle.
Downside
  • Heavy reliance on a few major EU CDMO partners could create lumpiness if clinical readouts are negative.
base case80% conf
Growth: 40

Quick takeaway

Full scale-up of Nectar project to 50% capacity in FY26.

Risk watch: Delays in Wave-2 projects (R32 expansion, MPP debottlenecking).

Show details (2 drivers, 2 risks)

Drivers

  • Full scale-up of Nectar project to 50% capacity in FY26.
  • Commissioning of 40k TPA AHF plant driving vertical integration.

Risks

  • Delays in Wave-2 projects (R32 expansion, MPP debottlenecking).
  • Continued input cost increases for sulfur and fluorspar.
upside case60% conf
Growth: 50

Quick takeaway

Faster than expected adoption of Opteon liquid cooling fluid in $3bn global market.

Risk watch: Potential global trade war tariffs affecting U.S. exports.

Show details (2 drivers, 2 risks)

Drivers

  • Faster than expected adoption of Opteon liquid cooling fluid in $3bn global market.
  • Margin expansion beyond 34.5% due to higher-than-expected R32 realization ($4.5-$6.5/kg).

Risks

  • Potential global trade war tariffs affecting U.S. exports.
  • Talent retention in highly technical CDMO space.
downside case40% conf
Growth: 25

Quick takeaway

Agchem pricing pressure persisting longer than expected.

Risk watch: Supply chain disruptions for key raw materials.

Show details (2 drivers, 2 risks)

Drivers

  • Agchem pricing pressure persisting longer than expected.
  • Forex tailwind reversal absorbing operating leverage gains.

Risks

  • Supply chain disruptions for key raw materials.
  • Under-utilization of new HFC capacity if global demand softens.

Story of the Stock - Top Strategies

No strategy data available

Business Segments

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...